Last reviewed · How we verify
Rifadin (Rifampicin)
At a glance
| Generic name | Rifampicin |
|---|---|
| Also known as | RIFADINE, Rifampin, RIF, Rofact, Rifadin |
| Sponsor | Sanofi Aventis Us |
| Drug class | Rifamycin Antibacterial [EPC] |
| Target | Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Acute tuberculosis
- Inactive tuberculosis
- Meningococcus carrier
- Prevention of Meningococcal Meningitis
- Pulmonary tuberculosis
Common side effects
- Diarrhea
- Hepatitis
- Shock-like syndrome with hepatic involvement
- Abnormal liver function tests
- Thrombocytopenia
- Cerebral hemorrhage
- Disseminated intravascular coagulation
- Transient leukopenia
- Hemolytic anemia
- Decreased hemoglobin
- Headache
- Fever
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (PHASE1)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifadin CI brief — competitive landscape report
- Rifadin updates RSS · CI watch RSS
- Sanofi Aventis Us portfolio CI